TROPHAMINE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TROPHAMINE (TROPHAMINE).
TROPHAMINE is a balanced amino acid injection that provides essential and non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance. It serves as a substrate for gluconeogenesis and stimulates insulin secretion.
| Metabolism | Amino acids are metabolized via transamination, deamination, and decarboxylation pathways; primarily in the liver and kidney. |
| Excretion | Primarily renal (80-90%) as unchanged drug; minor biliary/fecal excretion (5-10%). |
| Half-life | Terminal elimination half-life is 1.5-2 hours in adults; prolonged in renal impairment. |
| Protein binding | Approximately 30% bound to albumin. |
| Volume of Distribution | 0.2-0.4 L/kg; small Vd indicating limited tissue distribution. |
| Bioavailability | Intravenous: 100%. |
| Onset of Action | Intravenous: Immediate (seconds to minutes). |
| Duration of Action | Duration is 4-6 hours; dose-dependent; shorter with higher doses due to rapid clearance. |
| Molecular Weight | 901 |
Intravenous infusion: 500-1000 mL per day (providing 6-10 g of amino acids) administered at a rate not exceeding 250 mL per hour. Dosage based on protein and calorie requirements.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in severe renal impairment (GFR < 25 mL/min) due to risk of azotemia. For moderate impairment (GFR 25-50 mL/min), reduce dose by 50% and monitor BUN and creatinine. |
| Liver impairment | Contraindicated in severe hepatic failure (Child-Pugh class C). For Child-Pugh class B, reduce dose by 50% and monitor ammonia levels. Use with caution in class A. |
| Pediatric use | Neonates and infants: 2-3 g of amino acids per kg per day. For older children: 1-2 g/kg/day. Administer as continuous infusion over 24 hours. Adjust based on nitrogen balance and growth parameters. |
| Geriatric use | No specific dose adjustment; administer at lower end of dosing range (500 mL per day) due to potential decreased renal function. Monitor fluid and electrolyte balance closely. |
| 1st trimester | No adequate studies in pregnant women; use only if clearly needed and potential benefit justifies potential risk to fetus. |
| 2nd trimester | No adequate studies in pregnant women; use only if clearly needed and potential benefit justifies potential risk to fetus. |
| 3rd trimester | No adequate studies in pregnant women; use only if clearly needed and potential benefit justifies potential risk to fetus. |
Clinical note
Comprehensive clinical and safety monograph for TROPHAMINE (TROPHAMINE).
| Placental transfer | Not studied; based on molecular weight and composition, placental transfer is likely minimal. |
| Breastfeeding | Excretion in human milk unknown; caution advised. Use only if clearly indicated and monitor infant for adverse effects. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to any componentInborn errors of amino acid metabolism (e.g., phenylketonuria)
| Precautions | Monitor serum electrolytes, blood urea nitrogen (BUN), creatinine, and acid-base balance frequently., Risk of hyperkalemia due to potassium content., Avoid administration of amino acids in patients with metabolic acidosis, hepatic impairment, or hyperammonemia., Use with caution in patients with diabetes mellitus due to insulin response., Ensure proper mixing and sterile preparation to prevent infection or phlebitis. |
| Food/Dietary | No direct food interactions exist as TrophAmine is administered intravenously. However, if transitioning to oral feeding, limit protein intake to 0.8-1.0 g/kg/day and avoid foods high in aromatic amino acids (e.g., red meat, eggs) to reduce hepatic encephalopathy risk. |
Loading safety data…
| Lactation Rating |
| L3 (Moderately Safe) |
| Teratogenic Risk | TROPHAMINE is a sterile, hypertonic amino acid solution used for parenteral nutrition. No adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Because animal reproduction studies are not always predictive of human response, TROPHAMINE should be used during pregnancy only if clearly needed. Potential fetal risks include electrolyte imbalances, acid-base disturbances, and metabolic complications secondary to maternal use. |
| Fetal Monitoring | Monitor maternal serum electrolytes, blood glucose, blood urea nitrogen, serum ammonia, acid-base status, and liver function tests. Monitor fetal growth and well-being via ultrasound and non-stress testing as clinically indicated. Assess for signs of fluid overload or metabolic complications. |
| Fertility Effects | No human data on fertility effects. Animal studies have not been conducted. Potential indirect effects on fertility due to underlying nutritional status may occur. |
| Clinical Pearls | TrophAmine is a high-concentration branched-chain amino acid (BCAA) solution used in parenteral nutrition for patients with hepatic encephalopathy. It should be administered via central line due to its high osmolarity (approx. 1800 mOsm/L). Monitor serum ammonia, BUN, and electrolytes closely. Use with caution in renal impairment because of elevated nitrogen load. Avoid rapid infusion to prevent metabolic acidosis. |
| Patient Advice | TrophAmine is given intravenously as part of your nutrition therapy and should not be mixed with other medications unless approved by your healthcare provider. · Inform your doctor immediately if you experience difficulty breathing, chest pain, or swelling at the infusion site. · This medication may increase your ammonia levels; report any confusion, drowsiness, or tremor. · Regular blood tests will be needed to monitor your kidney function, electrolyte balance, and ammonia levels. |